Navigation Links
Macrocyclics presenta nuevos productos
Date:1/10/2014

DALLAS, 10 de enero de 2014 /PRNewswire/ -- Macrocyclics, Inc. (compañía de AREVA Med) anunció hoy la presentación de cuatro nuevos productos que ampliarán las aplicaciones de imágenes PET con cobre-64 y galio-68 usando plataformas quelatantes basadas en NOTA. Además, un nuevo conjugado de DOTA basado en serotonina ofrece el potencial para obtener imágenes de neurotransmisión serotoninérgicas utilizando un radioisótopo o con gadolinio mediante imágenes por resonancia magnética (MRI).

(Logo: http://photos.prnewswire.com/prnh/20130523/DA20136LOGO)

Visite www.macrocyclics.com para obtener más información.

MÁS ACERCA DE MACROCYCLICS
Macrocyclics es el líder global en tecnologías de agentes quelatantes de alto desempeño para la medicina desde 1995. El equipo de Macrocyclics se dedica a proveer a los clientes agentes quelatantes y servicios tanto establecidos como innovadores para superar los desafíos de las imágenes moleculares y la medicina nuclear. www.macrocyclics.com

MÁS ACERCA DE AREVA MED
AREVA Med es una subsidiaria de AREVA que se especializa en el desarrollo de tratamientos innovadores para luchar contra el cáncer. AREVA Med creó nuevos procesos para producir plomo-212 (²¹²Pb) de alta pureza, un metal poco común que actualmente se encuentra en el centro de prometedoras investigaciones de medicina nuclear. En 2011, AREVA Med adquirió Macrocyclics, líder global en tecnología de agentes quelatantes de alto desempeño. AREVA Med también formó alianzas con socios científicos de primer nivel, como el Instituto Nacional del Cáncer (National Cancer Institute, NCI), la Universid
'/>"/>

SOURCE Macrocyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Macrocyclics apresenta novos produtos
2. Macrocyclics introduces new products
3. Healthcare Companies Report Conference Presentation Schedule, Stock Price Updates, and Clinical Study Results - Research Report on Medivation, Envision Healthcare, Fonar, Idera Pharma, and Neurocrine
4. Presentation Schedules, Stock Movements, Agreements, and New Appointments - Research Report on Celgene, Merck, Bristol-Myers, Valeant, and Mylan
5. Cepheid to Webcast Upcoming Financial Presentation
6. Quarterly Dividends, Clinical Trial Results, Dental Exhibition Updates, and Upcoming Presentation Schedules - Research Report Quest Diagnostics, Avanir, Sirona, Ligand and Genomic Health
7. Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies
8. Cell Therapeutics Announces Presentation of Interim Results from Phase 2 Tosedostat Trial in Older Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) at ASH Annual Meeting
9. Ambit Announces Presentations At The 55th Annual Meeting Of The American Society Of Hematology (ASH)
10. Highland Instruments, Inc., Announces Presentation of "Effects of Electrosonic Stimulation on the Perception of Chronic Pain Due to Osteoarthritis of the Knee."
11. Nora Therapeutics Announces New Time for Presentation at the Oppenheimer 24th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014  Columbia Laboratories, Inc. (Nasdaq: ... of pharmaceutical development, clinical trial manufacturing, and advanced analytical ... that it will participate at the upcoming Rodman & ... be held in New York . ... on September 9, 2014 at the New York Palace ...
(Date:8/27/2014)... and NINGBO, China , Aug. ... Ningbo Menovo Pharmaceutical Co., Ltd, ("Menovo") today announced they ... of generic pharmaceuticals, primarily targeting the United ... agreement, Amerigen and Menovo will jointly develop products for ... . Menovo will be responsible for manufacturing API ...
(Date:8/27/2014)... Aug. 27, 2014 /CNW/ - Covalon Technologies Ltd. (the "Company" ... the following financial results for its third quarter of fiscal ... 2014: , Revenue of $1,291,378, a 13% decrease ... Net loss for the quarter of $240,156 compared to net ... year For the nine months ended June ...
Breaking Medicine Technology:Amerigen Pharmaceuticals Limited and the Ningbo Menovo Pharmaceutical Co., Ltd, today announced they had entered into a collaboration agreement regarding the development of generic pharmaceuticals, primarily targeting the United States market 2Covalon Announces Third Quarter Results 2Covalon Announces Third Quarter Results 3
... from Biodel Inc. (Nasdaq: BIOD ) reported ... basal insulin and stabilized glucagon development programs in poster ... Technology Meeting in Bethesda, MD.   Dr. ... double-blind, randomized crossover trial in 13 subjects with type ...
... (NYSE Amex: NBS ) ("NeoStem" or the ... revenues, global research and development capabilities and operations in ... adult stem cells, and China pharmaceuticals, is today providing ... Third Quarter Results Revenues for the nine ...
Cached Medicine Technology:Biodel Reports New Findings from Key Programs at Diabetes Technology Meeting 2Biodel Reports New Findings from Key Programs at Diabetes Technology Meeting 3Biodel Reports New Findings from Key Programs at Diabetes Technology Meeting 4Biodel Reports New Findings from Key Programs at Diabetes Technology Meeting 5NeoStem Provides Third Quarter Update 2NeoStem Provides Third Quarter Update 3
(Date:8/27/2014)... The genome we inherited from our parents shapes many ... genome we have an epigenome that is set during ... and environmental exposuresand perhaps by those of our parents ... on our DNA and supporting proteins that determine whether ... are deeply responsible for our own health, but also ...
(Date:8/27/2014)... growth in health care spending for commercially insured individuals ... services, rather than increased use, according to a new ... Health Policy & Clinical Practice, published in the August ... . , There is increasing concern that consolidation in ... faced by payers and, ultimately, consumers," said Carrie Colla, ...
(Date:8/27/2014)... NJ (PRWEB) August 27, 2014 ... leading pediatric practice, Hoboken Pediatrics has joined our ... Dr. Andrzej Klos, Dr. Piotr Oko, Dr. Yanina ... Hundreds of highly skilled and experienced physicians comprise ... top doctors and practices in Hudson County, representing ...
(Date:8/27/2014)... Scientists at The Scripps Research Institute (TSRI) have ... can be associated with alcohol dependence. , This ... type 1 (Nf1), which TSRI scientists found is linked ... Nf1 regulates gamma-aminobutyric acid (GABA), a neurotransmitter that lowers ... novel and seminal study provides insights into the cellular ...
(Date:8/27/2014)... Silver Spring and Germantown, Md., and Denver (PRWEB) August ... healthcare real estate developer , has broken ground ... on the new Holy Cross Health hospital campus in ... of Bethesda, Md. Germantown is the third most populous ... medical office building on the Holy Cross Germantown Hospital ...
Breaking Medicine News(10 mins):Health News:Scientists map the 'editing marks' on fly, worm, human genomes 2Health News:Scientists map the 'editing marks' on fly, worm, human genomes 3Health News:Scientists map the 'editing marks' on fly, worm, human genomes 4Health News:Tracking spending among the commercially insured 2Health News:Hoboken Pediatrics Joins CarePoint Health Medical Group 2Health News:Hoboken Pediatrics Joins CarePoint Health Medical Group 3Health News:Scripps Research Institute scientists link alcohol-dependence gene to neurotransmitter 2Health News:NexCore Breaks Ground on Medical Office Building on Holy Cross Health Campus in Germantown, Maryland 2Health News:NexCore Breaks Ground on Medical Office Building on Holy Cross Health Campus in Germantown, Maryland 3Health News:NexCore Breaks Ground on Medical Office Building on Holy Cross Health Campus in Germantown, Maryland 4
... Since mephedrone was made illegal in the UK in 2010, the ... degraded, which in turn may have reduced use of the drug. ... continued to use mephedrone after it became illegal would switch to ... by their friends or on the Internet. They would be ...
... health records (EHRs) are rapidly becoming part of the ... of care. In the first large study of its ... Nursing determined that nurses working with EHRs consistently reported ... for patients than nurses working in hospitals without this ...
... , TUESDAY, Jan. 17 (HealthDay News) -- With the Alzheimer,s ... ages, a panel of experts is meeting for two days ... fast emerging as one of the nation,s biggest -- and ... is to improve diagnosis, buttress support and training programs for ...
... drug called regorafenib slowed the progression of tumors and lengthened ... an international phase III clinical trial found. The findings were ... American Society of Clinical Oncology in San Francisco by ... principal investigator of the trial in the United States. ...
... are performed on all newborns born in the U.S. ... are not apparent at birth. These newborn screening programs ... early and improve outcomes in potentially devastating conditions. ... the data collection linked to newborn screening results, aiming ...
... Jan. 16, 2012 Listen up, pedestrians wearing headphones. ... Many probably can,t, especially young adult males. Serious ... in six years, according to new research from the University ... Medical Center in Baltimore. In many cases, the cars ...
Cached Medicine News:Health News:Despite the risks, mephedrone users in the UK are ready to try the next legal high 2Health News:Better together - The RN and the EHR 2Health News:U.S. Wants to Buttress Alzheimer's Arsenal by 2025 2Health News:U.S. Wants to Buttress Alzheimer's Arsenal by 2025 3Health News:Drug improves survival of colorectal cancer patients, trial results show 2Health News:Newborn screening program aims to help transform treatments for genetic diseases detected at birth 2Health News:Newborn screening program aims to help transform treatments for genetic diseases detected at birth 3Health News:University of Maryland study: Headphone-distracted pedestrians face death, serious injury 2Health News:University of Maryland study: Headphone-distracted pedestrians face death, serious injury 3
The Onar®Lp test system is an in vitro test for the qualitative diagnosis of legionella in clinical samples....
The Onar®Lp -QP test system is an in vitro test for the quantitative diagnosis of legionella in clinical samples....
Designed for OSA patients who have difficulty with conventional CPAP therapy, the ResMed SULLIVAN Comfort system is a solution for those who need an alternative to CPAP....
... an approach to treatment that ... pressure range to 25 cm ... treat patients with severe OSA. ... integrated humidification and built-in Encore® ...
Medicine Products: